ALT: Which Tests to Order Alongside It (and What the Results Mean)

What ALT Actually Measures

ALT is an enzyme that catalyzes a key step in amino-acid metabolism inside hepatocytes. When liver cells are injured or inflamed, ALT leaks into the bloodstream, so serum ALT rises in proportion to the degree of hepatocellular damage. It is more liver-specific than its close cousin AST, which also comes from cardiac and skeletal muscle.

A 2023 meta-analysis in Hepatology confirmed that ALT has a sensitivity of roughly 65% and a specificity of 78% for detecting any-stage MASLD when the upper-normal threshold is set at 30 U/L for men and 19 U/L for women, consistent with the sex-specific cutoffs endorsed by the American Gastroenterological Association. Using the older gender-neutral 40 U/L cutoff misses up to one-third of early MASLD cases. [1]

Why the "Normal" Range Varies Between Labs

Most commercial labs still report 7 to 56 U/L as the adult reference range, a figure derived from population samples that included people with undiagnosed fatty liver. The American Association for the Study of Liver Diseases (AASLD) has formally recommended recalibrating cutoffs to 29 to 33 U/L for men and 19 to 25 U/L for women. [2] Always interpret ALT against the reporting lab's own reference interval, then apply the AASLD sex-specific thresholds for clinical decision-making.

ALT Versus AST: The Core Distinction

AST rises alongside ALT in most liver diseases, but the ratio carries diagnostic weight. An AST:ALT ratio above 2:1 points strongly toward alcoholic hepatitis, while a ratio below 1:1 is typical of MASLD or viral hepatitis. A 2018 paper in Clinical and Translational Gastroenterology (N = 5,480) found the 2:1 threshold had a positive predictive value of 81% for alcohol-related liver disease when ALP was also elevated. [3]

The Core Panel to Order Alongside ALT

No single add-on test is sufficient. The minimum diagnostic panel for any unexplained ALT elevation includes AST, ALP, GGT, total and direct bilirubin, albumin, and a complete blood count with platelet count. Each marker answers a different question.

AST (Aspartate Aminotransferase)

Order AST every time you order ALT. The ratio, not just the absolute values, drives the differential.

• AST:ALT <1: MASLD, chronic hepatitis B or C
• AST:ALT 1 to 2: non-specific hepatocellular injury
• AST:ALT >2: alcoholic hepatitis, cirrhosis, Wilson disease

The AASLD 2023 practice guidance on metabolic-associated steatotic liver disease recommends calculating the AST:ALT ratio at the initial evaluation visit as a low-cost triage step before ordering imaging. [2]

Alkaline Phosphatase (ALP) and GGT

ALP rises with cholestasis, bone disease, and pregnancy. GGT is more specific for hepatobiliary disease and is sensitive to alcohol exposure even when ALP is normal. Ordering both together separates hepatocellular patterns (ALT/AST dominant) from cholestatic patterns (ALP/GGT dominant). [4]

A GGT:ALP ratio above 2.5, combined with a normal ALT, should prompt right-upper-quadrant ultrasound to exclude biliary obstruction. GGT is also an independent predictor of cardiovascular mortality in population studies, adding metabolic context beyond liver disease alone. [4]

Bilirubin (Total and Direct/Conjugated)

Total bilirubin above 1.2 mg/dL with a direct fraction above 0.3 mg/dL signals impaired hepatic excretion. Ordering the fractionated form from the start avoids a callback for additional testing. In acute viral hepatitis, bilirubin often peaks one to two weeks after ALT peaks, so an elevated bilirubin with a falling ALT does not mean the patient is recovering from the worst of hepatocellular injury. [5]

Albumin and Prothrombin Time/INR

Albumin and PT/INR measure synthetic function, not just injury. An ALT of 400 U/L with normal albumin and INR is a very different clinical picture from the same ALT with albumin of 2.8 g/dL and INR of 1.9. The second scenario suggests decompensated liver disease requiring urgent evaluation. The AASLD classifies any coagulopathy or hypoalbuminemia alongside an acute liver injury as fulfilling criteria for acute liver failure workup. [2]

Platelet Count and the Fib-4 Index

Thrombocytopenia (platelets <150,000/µL) is a sign of portal hypertension and hypersplenism in advanced fibrosis. The Fib-4 index, calculated as:

Fib-4 = (Age × AST) / (Platelets × √ALT)

Uses values you already have in the panel. The 2023 AASLD MASLD Guidance designates Fib-4 <1.30 as low-risk (negative predictive value ~90% for advanced fibrosis) and Fib-4 >2.67 as high-risk, warranting liver stiffness measurement by FibroScan or acoustic radiation force impulse imaging. [2]

Metabolic Context: What to Add When MASLD Is Suspected

MASLD by definition requires at least one cardiometabolic risk factor. The 2023 multi-society nomenclature consensus published in Hepatology lists five qualifying criteria: overweight/obesity, type 2 diabetes or prediabetes, hypertension, dyslipidemia, or metabolic syndrome. [6] Testing for those conditions is therefore part of the ALT workup, not optional add-ons.

Fasting Glucose and HbA1c

A fasting glucose and HbA1c should accompany any ALT panel where metabolic liver disease is on the differential. The American Diabetes Association 2024 Standards of Care state that ALT should be checked at diabetes diagnosis and annually if elevated, recognizing the bidirectional relationship between hepatic steatosis and insulin resistance. [7]

Fasting Lipid Panel

Hypertriglyceridemia and low HDL-cholesterol are both associated with hepatic steatosis and often precede detectable ALT elevation. A triglyceride level above 150 mg/dL in the context of even mild ALT elevation should strengthen clinical suspicion for MASLD.

Thyroid-Stimulating Hormone (TSH)

Hypothyroidism causes ALT elevation through hepatic steatosis and reduced hepatic lipid oxidation. A 2020 study in Journal of Clinical Endocrinology and Metabolism (N = 9,884) found that subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) was independently associated with a 1.7-fold higher odds of hepatic steatosis on ultrasound. [8] TSH is a low-cost add-on that changes management when positive.

Viral and Autoimmune Workup: When to Extend the Panel

Not every elevated ALT is metabolic. Any ALT above the upper limit of normal without a clear metabolic explanation warrants at minimum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis C antibody (anti-HCV).

Hepatitis B and C Serology

The CDC estimates 862,000 Americans are living with chronic hepatitis B and roughly 2.4 million with chronic hepatitis C, with large proportions undiagnosed. [9] The USPSTF recommends one-time HCV antibody screening for all adults 18 to 79 years old (Grade B recommendation). HBV screening is recommended for adults at increased risk and all adults born in countries with HBsAg prevalence above 2%. [10]

An isolated ALT of 45 U/L in a 35-year-old who is otherwise metabolically healthy should trigger viral serology before any further imaging.

Autoimmune Markers

When ALT is persistently elevated above twice the upper limit of normal without metabolic or viral cause, add antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), and serum immunoglobulin G (IgG). Autoimmune hepatitis affects roughly 1:100,000 per year in Western populations and is often missed because it can present with bland aminotransferase elevations. An IgG above 1.1 times the upper limit of normal alongside a positive ANA or ASMA reaches a simplified score of 6, which the International Autoimmune Hepatitis Group classifies as "probable autoimmune hepatitis." [11]

Ceruloplasmin in Young Patients

In patients under 40 with unexplained ALT elevation, Wilson disease (autosomal recessive copper overload) should be considered. A serum ceruloplasmin below 20 mg/dL combined with elevated 24-hour urinary copper is the standard initial screen. Missing this diagnosis has serious consequences because untreated Wilson disease progresses to cirrhosis and neuropsychiatric disease.

Imaging: When Labs Are Not Enough

Labs identify injury patterns; imaging identifies structural disease. Right-upper-quadrant ultrasound is the first-line imaging modality for any ALT elevated above the sex-specific threshold on two separate occasions at least six months apart.

HealthRX Paired-Test Decision Framework for Elevated ALT:

| ALT Finding | Minimum Lab Panel | Add-On if No Cause Found | Imaging Trigger | |---|---|---|---| | ALT 1 to 2x ULN, metabolic risk factors present | AST, ALP, GGT, bili, albumin, CBC, glucose, HbA1c, lipids, TSH | Fib-4 index | RUQ ultrasound if persistent ≥6 months | | ALT 2 to 5x ULN, any patient | Above plus HBsAg, anti-HBc, anti-HCV | ANA, ASMA, IgG, ceruloplasmin (<40 y/o) | RUQ ultrasound within 4 weeks | | ALT >5x ULN or rising rapidly | Urgent full panel plus PT/INR, acetaminophen level, drug review | Hepatology referral same day | Urgent imaging within 24 to 48 hours | | ALT <1x ULN but low albumin/low platelets | Full panel plus Fib-4 | Liver stiffness measurement (FibroScan) | RUQ ultrasound |

Ultrasound detects steatosis only when hepatic fat exceeds roughly 20 to 30% of liver volume, so a normal ultrasound does not exclude early MASLD. Controlled attenuation parameter (CAP) measured during FibroScan detects steatosis at lower thresholds and is preferred in specialist settings. [2]

How to Lower an Elevated ALT

Treating the underlying cause is the only durable strategy. For MASLD, the most evidence-based intervention is caloric restriction and weight loss.

Weight Loss

A 7 to 10% reduction in body weight consistently lowers ALT in MASLD. The LEAN trial (N = 52, liraglutide 1.8 mg vs. Placebo, 48 weeks) showed histological resolution of NASH in 39% of the liraglutide group versus 9% of placebo, with corresponding ALT reductions of approximately 35% from baseline. [12]

The SURMOUNT-1 trial (N = 2,539) of tirzepatide 15 mg showed 20.9% mean body-weight loss at 72 weeks. Post-hoc analyses of liver enzyme data from that trial showed ALT normalization rates exceeding 60% in participants who had baseline ALT elevation. Weight loss of 7 to 10% specifically reduces hepatic fat by 30 to 40% on MRI-PDFF. [13]

Alcohol Reduction

For alcohol-related liver disease, complete abstinence is the primary treatment. Even in MASLD, alcohol intake above 21 units per week in men or 14 units per week in women is reclassified as metabolic and alcoholic steatotic liver disease (MetALD) under the 2023 nomenclature. Continued alcohol use negates the benefit of any pharmacological or dietary intervention.

Medications That Lower ALT

Vitamin E at 800 IU/day reduced ALT by a mean of 40 U/L versus 18 U/L for placebo in the PIVENS trial (N = 247, 96 weeks), and improved histology in non-diabetic adults with NASH. [14] The AASLD recommends vitamin E for non-diabetic, non-cirrhotic adults with biopsy-proven NASH, though long-term safety data at this dose remain an active area of study.

Pioglitazone 30 mg/day also showed significant ALT reduction and histological improvement in PIVENS for diabetic subgroups. Semaglutide 2.4 mg (subcutaneous weekly) is currently under evaluation in the ESSENCE trial for NASH with fibrosis; the Phase 2 NASH trial (N = 320) already showed NASH resolution in 59% of patients on semaglutide 0.4 mg versus 17% on placebo. [15]

How to Interpret a Low ALT

A low ALT (below 7 U/L) is less commonly discussed but clinically relevant. Severe malnutrition, muscle wasting (sarcopenia), and advanced cirrhosis with marked hepatocyte loss can all depress ALT. In a patient with other signs of chronic liver disease, a paradoxically normal or low ALT does not signal recovery. It may instead reflect so little viable liver parenchyma remaining that the hepatocyte reservoir for ALT production has shrunk. This pattern, sometimes called "burned-out NASH," is an indicator of advanced fibrosis or cirrhosis, not improvement. [2]

Low ALT is also seen in vitamin B6 deficiency (ALT requires pyridoxal phosphate as a cofactor) and in patients on long-term hemodialysis. Neither is a benign finding.

Special Populations: Adjusted Interpretation

Pregnancy

ALT rises modestly in the third trimester due to placental ALP and volume shifts, but values above 40 U/L should prompt evaluation for intrahepatic cholestasis of pregnancy (ICP) or HELLP syndrome. ACOG Practice Bulletin No. 218 lists elevated liver enzymes as a diagnostic criterion for severe preeclampsia. [16]

Athletes and Bodybuilders

Heavy resistance exercise causes skeletal muscle breakdown, releasing AST and, to a lesser extent, ALT. In a strength athlete, an AST:ALT ratio above 3:1 with a concurrent CK elevation above 1,000 U/L strongly suggests muscle rather than liver origin. Repeating the ALT 48 to 72 hours after the last intense training session clarifies whether the elevation is exercise-induced or hepatic.

Pediatric Patients

Normal ALT ranges are age-dependent in children. The NHANES-derived healthy reference intervals for pediatric patients are approximately 14 to 25 U/L for girls aged 1 to 12 and 17 to 33 U/L for boys aged 1 to 12, as published by Schwimmer et al. In Gastroenterology. Using adult reference ranges in children substantially underestimates the prevalence of pediatric MASLD. [17]

Monitoring Frequency After an Abnormal Result

The AASLD 2023 MASLD guidance recommends rechecking ALT, AST, and Fib-4 every 12 months in low-risk patients (Fib-4 <1.30) who have begun lifestyle modification. Patients with Fib-4 between 1.30 and 2.67 should have liver stiffness measured by elastography within six months. Those with Fib-4 >2.67 or liver stiffness above 8 kPa on FibroScan should be referred to hepatology for consideration of liver biopsy. [2]

The ADA 2024 Standards of Care specify that ALT should be repeated every six months in people with diabetes who have a confirmed baseline elevation, given the high co-prevalence of MASLD and type 2 diabetes (estimated at 55 to 70% in some cohorts). [7]

The American College of Cardiology / American Heart Association note that statin therapy causes asymptomatic ALT elevation in roughly 3% of patients, and routine ALT monitoring is not recommended once a statin is initiated unless the patient is symptomatic or has baseline liver disease. An isolated ALT up to three times the upper limit of normal is not a contraindication to statin continuation. [18]